Most cited papers from Centre Oscar Lambret

Centre Oscar Lambret

What are the most cited papers from Centre Oscar Lambret?

The most cited paper from Centre Oscar Lambret is "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer" (Thierry Conroy, Françoise Desseigne, Marc Ychou et al., 2011), with 7,927 citations. Next come "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial" (5,563) and "Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer" (3,214).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 333 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine Open access	11 May 2011	7,927
2	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell et al. · The Lancet Oncology Open access	30 Jan 2012	5,563
3	Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, Christian Domenge, Mahmut Özsahin et al. · New England Journal of Medicine Open access	5 May 2004	3,214
4	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study Aurélien Marabelle et al. · Journal of Clinical Oncology Open access	4 Nov 2019	3,072
5	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Axel F. Grothey, Eric Van Cutsem, Alberto Felice Sobrero et al. · The Lancet	21 Nov 2012	2,934
6	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Michael Weller et al. · Nature Reviews Clinical Oncology ReviewOpen access	8 Dec 2020	2,063
7	Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial Mila Donker et al. · The Lancet Oncology Open access	15 Oct 2014	1,891
8	Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) Jacques Bernier, Jay Scott Cooper, Thomas F. Pajak et al. · Head & Neck	2005	1,782
9	Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer Jan Baptist Vermorken, Éva Remenár, Carla van Herpen et al. · New England Journal of Medicine Open access	24 Oct 2007	1,726
10	Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial J.-L. Lefebvre, Dominique Chevalier, Bernard Luboinski et al. · JNCI Journal of the National Cancer Institute	3 Jul 1996	1,340
11	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions Patrick Yung Wen et al. · Neuro-Oncology Open access	20 Apr 2020	1,183
12	Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study Marianne Nordsmark, Søren Møller Bentzen, Volker Rudat et al. · Radiotherapy and Oncology	12 Aug 2005	953
13	Morphine and alternative opioids in cancer pain: the EAPC recommendations G.W. Hanks, Franco De Conno, Nathan I. Cherny et al. · British Journal of Cancer Open access	2001	861
14	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC Benjamin Besse et al. · OncoImmunology Open access	12 Aug 2015	809
15	Carbon monoxide poisoning — a public health perspective James A. Raub, Monique Mathieu-Nolf, Neil B. Hampson et al. · Toxicology	Apr 2000	806
16	A phase II study Philippe Rougier, Antoine Adenis, Michel Pierre Ducreux et al. · European Journal of Cancer	May 2000	752
17	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology	Nov 2012	748
18	Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas Jean‐Michel Coindre, Philippe Terrier, Louis Guillou et al. · Cancer	2001	744
19	EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours Émilie Le Rhun, Michael Weller, Dieta Brandsma et al. · Annals of Oncology Open access	5 May 2017	649
20	Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Vincent Grégoire, J. -L. Lefebvre, Lisa Francesca Licitra et al. · Annals of Oncology Open access	May 2010	624
21	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial P. Joly et al. · The Lancet	22 Mar 2017	622
22	Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study Pierre Soubeyran, Carine A. Bellera, Jean Goyard et al. · PLoS ONE Open access	11 Dec 2014	601
23	Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial Élisabeth Quoix et al. · The Lancet	13 Aug 2011	578
24	Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Jacques Bonneterre, Aman U. Buzdar, Jean‐Marc Nabholtz et al. · Cancer	2001	576
25	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study Isabelle Ray‐Coquard, Jean‐Yves Blay, Antoîne Italiano et al. · The Lancet Oncology	16 Oct 2012	575
26	Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO) Marcos Ballester, Gil Dubernard, Fabrice R Lecuru et al. · The Lancet Oncology	13 Apr 2011	574
27	Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease Marta Llopis et al. · Gut	7 Dec 2015	566
28	Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Laurent Arnould, M Gelly, Frederique Madeleine Penault-Llorca et al. · British Journal of Cancer Open access	2006	539
29	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma Yuichiro� Doki et al. · UCL Discovery (University College London) Open access	3 Feb 2022	532
30	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus Manish A. Shah, Takashi Kojima, Daniel Hochhauser et al. · JAMA Oncology Open access	20 Dec 2018	524
31	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer Timothy R. Rebbeck et al. · JAMA Open access258 authors	7 Apr 2015	517
32	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients Ben Alman et al. · European Journal of Cancer Open access	28 Jan 2020	508
33	Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial S. Gourgou-Bourgade, Caroline Mollévi, Françoise Desseigne et al. · Journal of Clinical Oncology Open access	4 Dec 2012	507
34	Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer et al. · Annals of Oncology Open access609 authors	10 Oct 2022	477
35	Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study Michele Maio, Paolo A. Ascierto, L. V. Manzyuk et al. · Annals of Oncology Open access	6 Jun 2022	471
36	Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations Fádi Fakhouri, Lubka T. Roumenina, François Provôt et al. · Journal of the American Society of Nephrology Open access	4 Mar 2010	469
37	ERBB2 oncogene in human breast cancer and its clinical significance Françoise Révillion, Jacques M Bonneterre, Jean‐Philippe Peyrat · European Journal of Cancer	May 1998	458
38	Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · The Lancet Oncology	17 Feb 2014	455
39	Depression, quality of life and breast cancer: a review of the literature Michel Reich, A. Lesur, C. Perdrizet-Chevallier · Breast Cancer Research and Treatment	2 Aug 2007	446
40	Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies Hyun Cheol Chung et al. · Journal of Thoracic Oncology Open access	20 Dec 2019	445
41	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients Myriam Delaunay et al. · European Respiratory Journal Open access	Aug 2017	427
42	Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study Jean Louis Lefèbvre et al. · Journal of Clinical Oncology Open access	23 Jan 2013	422
43	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) B. Kasper et al. · Annals of Oncology Open access	22 Jun 2017	419
44	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) Fabrice André, Thomas Bachelot, Frédéric Commo et al. · The Lancet Oncology	6 Feb 2014	418
45	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis Céline Lefèbvre et al. · PLoS Medicine Open access	27 Dec 2016	413
46	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas Maud Toulmonde, Nicolas Penel, Julien Adam et al. · JAMA Oncology Open access	29 Jun 2017	408
47	Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial Éric Rullier, Philippe Rouanet, Jean‐Jacques Tuech et al. · The Lancet	8 Jun 2017	393
48	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group Benjamin Lacas et al. · Radiotherapy and Oncology ReviewOpen access105 authors	27 Jan 2021	391
49	Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial Sanne A. L. Bartels et al. · Journal of Clinical Oncology Open access	16 Nov 2022	389
50	Improved survival using specialized multidisciplinary board in sarcoma patients Jean‐Yves Blay et al. · Annals of Oncology Open access	25 Aug 2017	382

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.